Skip Ribbon Commands
Skip to main content

Study Results

The CAVD’s Data & Materials Sharing Agreement states that the consortium whose members provided material used to generate the data from a standardized assay will then make reasonable efforts to disseminate such data to the broader scientific community. The following table provides links to the results from a number of studies conducted using standardized assays.

Click the "Public Study Title" to view the details of the study or click the "Study Overview and Results" to view the study results.

To search for a specific study, use the search box above the table.  Typical search logic using "OR" and "AND" is supported.  For example, Plasma OR Protein.

  
  
  
  
Serum neutralization responses in rabbits to BG505 SOSIP.664 gp140, with or without GSK’s AS01B adjuvant.681.01Montefiori VIMCView Study Results
Characterization and epitope mapping of potential novel bNAbs "LN02" (Pantaleo_PA_623)623Montefiori VIMCView Study Results
Characterization and epitope mapping of Atreca Abs (Pantaleo_PA_633.02)633.02Montefiori VIMCView Study Results
Characterization and epitope mapping of potential novel bNAbs "LN02" (Pantaleo_PA_623.01)623.01Montefiori VIMCView Study Results
Characterization and epitope mapping of potential novel bNAbs "LN02" (Pantaleo_PA_623.02)623.02Montefiori VIMCView Study Results
Characterization of MPER specific antibodies elicited by MPER/liposome immunization in a mouse model666Montefiori VIMCView Study Results
1.1.2 antibody neuts – Unique ID 572572Montefiori VIMCView Study Results
Screening for bNAbs in HIV infected Patients474.01Montefiori VIMCView Study Results
Plasma depletion to identify bNAb epitopes615.01Montefiori VIMCView Study Results
Characterization and epitope mapping of Atreca Abs (Pantaleo_PA_633)633Montefiori VIMCView Study Results
Characterization and epitope mapping of Atreca Abs (Pantaleo_PA_633.01)633.01Montefiori VIMCView Study Results
Programming the magnitude and durability of HIV-1 clade C 1086.C envelope...432Montefiori VIMCView Study Results
To compare the spectrum of neutralizing activity by three candidate clinical clones of PGDM1400554Montefiori VIMCView Study Results
Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site609Montefiori VIMCView Study Results
PC301-Gates Therapeutic Vaccine459Montefiori VIMCView Study Results
Epitope mapping of mAbs from a Clade B, HIV-1 infected Elite Controller500Montefiori VIMCView Study Results
NHP Study 1601-VSVΔG HIV EnvBG505 chimera study investigating the effect of pseudotyping and route on vaccine efficacy. 563Montefiori VIMCView Study Results
NHP Study 1601-VSVΔG HIV EnvBG505 chimera study investigating the effect of pseudotyping and route on vaccine efficacy. 563.02Montefiori VIMCView Study Results
NHP Study 1601-VSVΔG HIV EnvBG505 chimera study investigating the effect of pseudotyping and route on vaccine efficacy. 563.03Montefiori VIMCView Study Results
NHP Study 1601-VSVΔG HIV EnvBG505 chimera study investigating the effect of pseudotyping and route on vaccine efficacy. 563.04Montefiori VIMCView Study Results
Identification of novel targets in elite controllers with neutralizing activity678Montefiori VIMCView Study Results
Evaluation of modified bNAbs564Montefiori VIMCView Study Results
Preclinical safety and immunogenicity - BG505 SOSIP.664 gp140/ AS01B Immunogenicity Assessment of Rabbit Sera from Citoxlab Study No. 1017-2324 681Montefiori VIMCView Study Results
Neuts on RV306 rmAbs from Single Cell Sorts – Unique ID 659659Montefiori VIMCView Study Results
VSV NHP Study-ADCC Assays548.01Montefiori VIMCView Study Results
Immune response in rabbits to eOD-GT8 60mer, with or without GSK’s AS01B adjuvant. 679Montefiori VIMCView Study Results
PK analysis of optimized 10-1074-LS variants in human FcRn knock-in mice649Montefiori VIMCView Study Results
Neutralization with recombinantly expressed monoclonal antibodies isolated from RV328 vaccinees – Unique ID 632.01632.01Montefiori VIMCView Study Results
Sequential immunization strategies to elicit bNAbs in PGT121 knock in mice and wild type mice.494.02Montefiori VIMCView Study Results
Optimal Antibody Combinations and Bispecifics for Prevention of HIV Subtype A, C and D Infections580Montefiori VIMCView Study Results
Optimal Antibody Combinations with LN01 for HIV Prevention582Montefiori VIMCView Study Results
PK analysis of optimized 3BNC117-LS variants in human FcRn knock-in mice650Montefiori VIMCView Study Results
Neutralization with recombinantly expressed monoclonal antibodies isolated from RV306 vaccinees643.01Montefiori VIMCView Study Results
Neutralization Breadth and Potency of 10E8-like bnAbs Expressed as IgG1 and IgG3657Montefiori VIMCView Study Results
Confirming the Efficacy of Virosomes Targeting gp41 in Indian Rhesus Macaques - Antibody Binding Assays IgG and IgA608.01Montefiori VIMCView Study Results
Investigating monoclonal antibody neutralization breadth and potency after delayed and repetitive boosting with ALVAC-HIV and AIDSVAX B/E527Montefiori VIMCView Study Results
Assaying Ig containing memory B cell culture supernatants for autologous tier 2 neutralization632Montefiori VIMCView Study Results
Assaying neutralization breadth and potency of recombinantly expressed antibodies isolated from RV305 leukapheresis samples528Montefiori VIMCView Study Results
Evaluating immunogenicity of TLR (7/8) agonist (3M052) formulations and a HIV-1 envelope based vaccine in rhesus macaques499Montefiori VIMCView Study Results
Assaying Ig containing memory B cell culture supernatants for autologous tier 2 neutralization643Montefiori VIMCView Study Results
Investigating monoclonal antibody neutralization breadth and potency after delayed and repetitive boosting with ALVAC-HIV and AIDSVAX B/E611Montefiori VIMCView Study Results
DNA Protein PhI653Montefiori VIMCView Study Results
RepliVax Immunogenicity NHP Pilot Study498Montefiori VIMC, Koup VIMCView Study Results
653116- 952284 Plasma Neut Assays615Montefiori VIMCView Study Results
Screening for Neutralizing Antibody Breadth_3_2016560Montefiori VIMCView Study Results
Neutralizing Activity of CD4bs bNAb N6 against HIV-1 Clade C553Montefiori VIMCView Study Results
Phase 1 Evaluation of bNAb 10-1074514Montefiori VIMCView Study Results
RV328 Plasma Neut Assays on Pub ID 328039631Montefiori VIMCView Study Results
Analysis of neutralization activity in serum of immunized PGT121 knock-in mice.494.01Montefiori VIMCView Study Results
Multi-Specific Antibodies and Variants539Montefiori VIMCView Study Results
NHP Immuongenicity Study of Heterologous N7 Prime-Boost Immunization- MX1451Montefiori VIMC, Koup VIMCView Study Results
Immunogenicity and antigenicity of variable loop optimized clade C gp140 Env trimers457Montefiori VIMCView Study Results
Mouse 10E8-like bnAb Pre-Pilot PK Study565Montefiori VIMCView Study Results
NHP208_dosing study625Montefiori VIMCView Study Results
Ms333_non-GMP Potency626Montefiori VIMCView Study Results
Confirming the Efficacy of Virosomes Targeting gp41 in Indian Rhesus Macaques - Neutralization Assays608Montefiori VIMCView Study Results
Confirming the Efficacy of Virosomes Targeting gp41 in Indian Rhesus Macaques - Antibody Dependent Cellular Cytotoxicity Assays608.02Montefiori VIMCView Study Results
Confirming the Efficacy of Virosomes Targeting gp41 in Indian Rhesus Macaques - Antibody Fc Array Measurements608.03Montefiori VIMCView Study Results
Probing the Neutralizing Activity of DH511 Lineage Members against a Panel of Clade C Early/Acute HIV-1 Env Pseudoviruses621Montefiori VIMCView Study Results
Discovery & Characterization of bnAbs494.01Montefiori VIMCView Study Results
Humoral response in an NHP vaccination model using RhCMV/SIV followed by homologous or heterologous challenge460Montefiori VIMCView Study Results
Neutralization screening of B cell culture supernatants from leukepheresis samples from vacinees RV305_079 and RV305_018550Montefiori VIMCView Study Results
Neutralization of Memory B-cell Supernatants from RV305 Vacinees571Montefiori VIMCView Study Results
Analysis of neutralization activity in the serum of human Ig knock-in mice immunized with Envelope-based immunogens494Montefiori VIMCView Study Results
Screening for bNabs in HIV infected Patients474Montefiori VIMCView Study Results
ADCC activity of multi-specific antibodies566Montefiori VIMCView Study Results
Non-human primate challenge study comparing Vesicular Stomatitis Virus (VSV) vectors transiently and stably expressing the VSV G glycoprotein548Montefiori VIMCView Study Results
Neutralization Activity of DH511 Lineage Chimeric HIV gp41 Distal MPER Broadly Neutralizing Antibodies536Montefiori VIMCView Study Results
Epitope Mapping and Development of Neutralization Breadth in a gp41 Distal MPER Broadly Neutralizing Antibody (bnAb) Clonal Lineage503Montefiori VIMCView Study Results
Neutralization Activity of MPER bnAb DH517 against a Panel of COT6.15 Env Pseudoviruses529Montefiori VIMCView Study Results
In vitro activity of HIV multi-specific antibodies539Montefiori VIMCView Study Results
A phase 2, open label study of the safety, antiretroviral activity and pharmacokinetics of 3BNC117 during a short analytical treatment interruption in HIV-infected subjects482Montefiori VIMCView Study Results
Neutralization of eCD4-Ig variants 1v34 and 2v26521Montefiori VIMCView Study Results
Full-Length Single Chain (FLSC) Adjuvant Screening Study506Montefiori VIMCView Study Results
RV305 mAbs Differ in Strength and Breadth from RV144 mAbs532Montefiori VIMCView Study Results
Evaluation and comparison of the safety and immunogenicity of different priming strategies combining NYVAC, DNA and gp120 protein vaccines in non-human primates371Montefiori VIMC, Koup VIMCView Study Results
Evaluation and comparison of the safety and immunogenicity of prime-boost regimens combining different poxvirus vector-based and gp120 protein vaccines in non-human primates281Montefiori VIMC, Koup VIMCView Study Results
A phase 1 study of the safety, PK and antiretroviral activity of 3BNC117mAb in humans446Montefiori VIMC, Koup VIMCView Study Results
Studies to maximize immunogenicity by Env trimer stabilization and complement activation535Montefiori VIMCView Study Results
Comparison of env protein binding characteristics for IgG antibodies generated in mice after immunization with CD4-independent variants of HIV-1 envelopes523Montefiori VIMCView Study Results
Impact of IgG Subclass on Capacity to Mediate Neutralization of TH023.6454Montefiori VIMCView Study Results
Feb 2015_Development of bNAbs in HIV infection478Montefiori VIMCView Study Results
Immunogenicity of heterologous boost immunizations with MVA-CMDR, a modified vaccinia Ankara HIV-1 vaccine expressing Env gp 150/gag/pol, in HIV-uninfected volunteers previously immunized with DCVax-001 plus poly-ICLC579Montefiori and Koup VIMCView Study Results
Evaluating the impact in nonhuman primates of using nano particle formulated TLR 4 and 7 agonists for enhancing humoral immunity against HIV specific envelope protein immunogens - a study conducted by the Pulandran laboratory.355Montefiori VIMCView Study Results
Characterization of novel broadly neutralizing antibody LN01505Montefiori VIMCView Study Results
Characterization of novel broadly neutralizing antibody LN01505.01Montefiori VIMCView Study Results
RV305 vaccine regimen boosts RV144 plasma ADCC responses452Montefiori VIMCView Study Results
ART testing by MLV Neutralization Assay540Montefiori VIMCView Study Results
Evaluation of TV1.C and 1086.C gp120s lots from Research and Development via Immunogenicity in Guinea Pigs575Montefiori VIMCView Study Results
Evaluation of subtype B and E gp120s via Immunogenicity in Guinea Pigs576Montefiori VIMCView Study Results
Evaluation on the quality of gp120-specific antibody responses elicited by different glycan processed gp120s389Montefiori VIMCView Study Results
Targeting HIV-1 Env Gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques408Montefiori VIMC, Koup VIMCView Study Results
Targeting HIV-1 Env Gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques408Montefiori VIMC, Koup VIMCView Study Results
Rabbit Immunogenicity Study of Heterologous N7 Prime-Boost Immunization - RX2449Montefiori VIMCView Study Results
Rabbit Immunogenicity Study of Heterologous N7 Prime-Boost Immunization - RX2449Montefiori VIMCView Study Results
Neutralization assay using the MUC5AC at constant concentration of (0.5mg/ml) and serial dilution of HIV-1 antibody panel472Montefiori VIMCView Study Results
Neutralization assay using the MUC5AC at constant concentration of (0.5mg/ml) and serial dilution of HIV-1 antibody panel72Montefiori: VIMCView Study Results
CM244 neutralization activity of memory B cell culture supernatants and recombinant mAbs from an RV305 patient (PubID: RV305_094)504Montefiori VIMCView Study Results
mAbs from a subject in RV305 Neutralize Tier 2 Virus CNE8515Montefiori VIMCView Study Results
Neutralizing antibody responses and linear epitope specificity in RV305526Montefiori VIMCView Study Results
1 - 100Next